Application of the Euroimmun Anti-SARS-CoV-2-NCP (IgG) and Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) antibody tests to dried blood spots
RKI edoc (Robert Koch-Institut) · 2023-04-20
DOI: 10.25646/11228 ↗At a glance
Journal article in RKI edoc (Robert Koch-Institut), published on 2023-04-20. Written by Robert Koch-Institut.
Abstract (original language)
Application of the Euroimmun Anti-SARS-CoV-2-NCP (IgG) and Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) antibody tests to dried blood spotsA previous validation study during the first wave of the RKI-SOEP-study revealed an adapted cutpoint of 0.94 for classifying semiquantitative values of the Euroimmun Anti-SARS-CoV-2-S1-IgG ELISA antibody test in dried blood spot (DBS) samples [1].For the second wave of the study, different test assays were used.S-antibodies were analysed quantitatively (as opposed to the semiquantitative test in the first wave) using the Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) by Euroimmun.N-antibodies, which were not tested for in the first wave, were analysed semiquantitatively with the Anti-SARS-CoV-2-NCP (IgG) (also by Euroimmun).These tests are commonly used in the analysis of serum samples but were used on DBS in the second wave of the RKI-SOEP study [2] An additional validation study comparing serum with DBS results was therefore conducted in May and June 2022 to potentially optimize the cutpoint for DBS.244 employees of the RKI took part in the study after an institute-wide call for volunteers was published via email.Blood specimens were taken after participants' informed consent.The samples for all 244 participants could be evaluated.Results were reported back to participants anonymously and no additional information, e.g. on their age, sex, vaccination or infection history, was collected. Study execution and laboratory methodsFor each participant, the study team collected both a venous blood sample, which was processed into serum, and a capillary blood sample, which was processed into DBS.Both samples were then tested for IgG antibodies using the Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Anti-SARS-CoV-2-NCP (IgG) (both by Euroimmun AG, Lübeck, Germany).The results of the S-antibody test were quantitative, expressed in binding antibody units (BAU/mL) and classified for serum samples according to the manufacturer's specifications (positive: ≥ 35.2 BAU/mL, indeterminate ≥ 25.6 to < 35.2 BAU/mL, negative: < 25.6 BAU/mL).The results of the N-antibody test were semiquantitative ratio values which were classified for serum samples using the manufacturer-supplied cutpoints (positive: ratio ≥ 1.1; indeterminate: 0.8 ≤ ratio< 1.1, negative: ratio < 0.8).The quantitative assay was rerun with diluted samples for values above the upper detection limit, 27 samples remained above the upper detection limit even after dilution.After analysis, all samples were discarded. Statistical analysisThe aim of the analyses was to assess the test characteristics of the IgG test assays based on DBS compared to serum samples and, if appropriate, to derive an adapted cutpoint and, in case of the quantitative S-antibody test, a correction formula for DBS results so that the
Subjects
Cite
APA
Koch-Institut, R. (2023). Application of the Euroimmun Anti-SARS-CoV-2-NCP (IgG) and Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) antibody tests to dried blood spots. RKI edoc (Robert Koch-Institut). https://doi.org/10.25646/11228
Vancouver
Koch-Institut R. Application of the Euroimmun Anti-SARS-CoV-2-NCP (IgG) and Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) antibody tests to dried blood spots. RKI edoc (Robert Koch-Institut). 2023. doi:10.25646/11228
BibTeX
@article{KochInstitut2023,
author = {Koch-Institut, Robert},
title = {Application of the Euroimmun Anti-SARS-CoV-2-NCP (IgG) and Anti-SARS-CoV-2-QuantiVac-ELISA (IgG) antibody tests to dried blood spots},
journal = {RKI edoc (Robert Koch-Institut)},
year = {2023},
doi = {10.25646/11228}
}
EUVIMED